Hospira (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today presented new data showing Retacrit® (epoetin zeta) is as effective as epoetin alfa (Erypo®) in achieving and maintaining haemoglobin (Hb) levels in end-stage renal failure patients with diabetic nephropathy.1 The results from an analysis of two pivotal Phase III studies were presented at the annual meeting of the European Association for the Study of Diabetes (EASD). Continue reading ...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment